In a phase III study of alectinib, it significantly prolonged mPFS compared to crizotinib in treatment-naïve advanced ALK-positive NSCLC patients (34.8 vs 10.9 months; HR 0.43) [55, 56]. Here, ALK is linked to non-small cell lung carcinoma.